Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEF
Saswata S. Sarkar, Meredith A. Redd, James J. Hartman, Darren Ting‐Cheung Hwee, Anand Bat-Erdene, Leo H. Kim, Chihyuan Chuang, Cassady E. Rupert, Najah Abi‐Gerges, Janette Rodriguez, Desirae Martin, André deRosier, Samantha Edell, Yangsong Wu, Lisette Yco, , Fady I. Malik
This paper describes ulacamten, a novel cardiac myosin inhibitor with distinct binding and inhibitory properties compared to existing CMIs, showing efficacy in improving cardiac function in a rodent model of HFpEF.
bioRxiv · Jan 26, 2026 · PreprintBiochemistry